Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Lung Cancer

  Free Subscription

Articles published in J Nucl Med

Retrieve available abstracts of 38 articles:
HTML format

Single Articles

    July 2021
  1. ZHOU X, Jiang J, Yang X, Liu T, et al
    First-in-human evaluation of a PD-L1-binding peptide radiotracer in non-small cell lung cancer patients with PET.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262045. doi: 10.2967/jnumed.121.262045.
    PubMed     Abstract available

  2. ROHRICH M, Leitz D, Glatting FM, Wefers AK, et al
    Fibroblast Activation Protein specific PET/CT imaging in fibrotic interstitial lung diseases and lung cancer: a translational exploratory study.
    J Nucl Med. 2021 Jul 16. pii: jnumed.121.261925. doi: 10.2967/jnumed.121.261925.
    PubMed     Abstract available

  3. NIEMEIJER AN, Oprea Lager DE, Huisman MC, Hoekstra OS, et al
    First-in-human study of (89)Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer.
    J Nucl Med. 2021 Jul 16. pii: jnumed.121.261926. doi: 10.2967/jnumed.121.261926.
    PubMed     Abstract available

    May 2021
  4. GUBERINA M, Poettgen C, Metzenmacher M, Wiesweg M, et al
    J Nucl Med. 2021 May 20. pii: jnumed.120.260646. doi: 10.2967/jnumed.120.260646.
    PubMed     Abstract available

    January 2021
  5. LAFFON E, Marthan R
    Distribution Volume of (18)F-BMS-986192 in NSCLC Patients.
    J Nucl Med. 2021;62:144.

    December 2020
  6. STUSCHKE M, Pottgen C
    (18)F-FDG PET/CT for Target Volume Contouring in Lung Cancer Radiotherapy.
    J Nucl Med. 2020;61.

    November 2020
  7. AYATI N, Lee ST, Zakavi SR, Cheng M, et al
    Response evaluation and survival prediction following PD-1 immunotherapy in patients with non-small-cell lung cancer: comparison of assessment methods.
    J Nucl Med. 2020 Nov 27. pii: jnumed.120.254508. doi: 10.2967/jnumed.120.254508.
    PubMed     Abstract available

    October 2020
  8. CHRISTENSEN TN, Langer SW, Persson GF, Larsen KR, et al
    (18)F-FLT-PET/CT adds value to (18)F-FDG-PET/CT for diagnosing relapse after definitive radiotherapy in patients with lung cancer. Results of a prospective clinical trial.
    J Nucl Med. 2020 Oct 9. pii: jnumed.120.247742. doi: 10.2967/jnumed.120.247742.
    PubMed     Abstract available

    September 2020
  9. GALLDIKS N, Abdulla DS, Scheffler M, Wolpert F, et al
    Treatment Monitoring of Immunotherapy and Targeted Therapy using (18)F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences.
    J Nucl Med. 2020 Sep 4. pii: jnumed.120.248278. doi: 10.2967/jnumed.120.248278.
    PubMed     Abstract available

  10. CASTELLO A, Lopci E
    Reply: Diagnosis of Hyperprogressive Disease in Patients Treated with Checkpoint Inhibitors Using (18)F-FDG PET/CT.
    J Nucl Med. 2020;61:1405.

    June 2020
  11. GIESEL F, Adeberg S, Syed M, Lindner T, et al
    FAPI-74 PET/CT Using Either (18)F-AlF or Cold-kit (68)Ga-labeling: Biodistribution, Radiation Dosimetry and Tumor Delineation in Lung Cancer Patients.
    J Nucl Med. 2020 Jun 26. pii: jnumed.120.245084. doi: 10.2967/jnumed.120.245084.
    PubMed     Abstract available

  12. FERDINANDUS J, Barbato F, Chodyla M, Fendler WP, et al
    Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma.
    J Nucl Med. 2020 Jun 12. pii: jnumed.120.245803. doi: 10.2967/jnumed.120.245803.
    PubMed     Abstract available

    April 2020
  13. REYNOLDS JC, Maass-Moreno R, Thomas A, Ling A, et al
    FDG-PET assessment of malignant pleural mesothelioma: Total Lesion volume and Total Lesion Glycolysis; the central role of volume.
    J Nucl Med. 2020 Apr 13. pii: jnumed.119.238733. doi: 10.2967/jnumed.119.238733.
    PubMed     Abstract available

    February 2020
  14. SEBAN RD, Schwartz LH, Bonardel G, Dercle L, et al
    Diagnosis of Hyper-progressive Disease in Patients Treated with Checkpoint Inhibitors using (18)F-FDG PET/CT.
    J Nucl Med. 2020 Feb 21. pii: jnumed.120.242768. doi: 10.2967/jnumed.120.242768.

  15. HUISMAN M, Niemeijer AL, Windhorst B, Schuit R, et al
    Quantification of PD-L1 expression with [(18)F]BMS-986192 PET/CT in patients with advanced stage non-small-cell lung cancer.
    J Nucl Med. 2020 Feb 14. pii: jnumed.119.240895. doi: 10.2967/jnumed.119.240895.
    PubMed     Abstract available

    December 2019
  16. CASTELLO A, Rossi S, Toschi L, Mazziotti E, et al
    Hyper-progressive Disease in Patients With Non-Small Cell Lung Cancer Treated With Checkpoint Inhibitors: The Role of (18)F-FDG PET/CT.
    J Nucl Med. 2019 Dec 20. pii: jnumed.119.237768. doi: 10.2967/jnumed.119.237768.
    PubMed     Abstract available

  17. ARNON-SHELEG E, Haberfeld O, Kremer R, Keidar Z, et al
    Head to head prospective comparison of quantitative lung scintigraphy and segment counting in predicting pulmonary function of lung cancer patients undergoing video-assisted thoracoscopic lobectomy.
    J Nucl Med. 2019 Dec 20. pii: jnumed.119.234526. doi: 10.2967/jnumed.119.234526.
    PubMed     Abstract available

  18. ROSSI G, Bauckneht M, Genova C, Rijavec E, et al
    Comparison between 18F-FDG-PET- and CT-based criteria in non-small cell lung cancer (NSCLC) patients treated with Nivolumab.
    J Nucl Med. 2019 Dec 5. pii: jnumed.119.233056. doi: 10.2967/jnumed.119.233056.
    PubMed     Abstract available

    November 2019
  19. DISSAUX G, Visvikis D, Do-Ano R, Pradier O, et al
    Pre-treatment (18)F-FDG PET/CT Radiomics predict local recurrence in patients treated with stereotactic radiotherapy for early-stage non-small cell lung cancer: a multicentric study.
    J Nucl Med. 2019 Nov 15. pii: jnumed.119.228106. doi: 10.2967/jnumed.119.228106.
    PubMed     Abstract available

    June 2019
  20. JREIGE M, Dunet V, Letovanec I, Prior JO, et al
    Pulmonary lymphangitic carcinomatosis: diagnostic performance of HRCT and (18)F-FDG-PET/CT in correlation to clinical pathologic outcome.
    J Nucl Med. 2019 Jun 21. pii: jnumed.119.229575. doi: 10.2967/jnumed.119.229575.
    PubMed     Abstract available

    February 2019
  21. XING Y, Chand G, Liu C, Cook GJR, et al
    Early phase I study of a (99m)Tc labeled anti-PD-L1 single domain antibody in SPECT/CT assessment of programmed death ligand-1 expression in non-small cell lung cancer.
    J Nucl Med. 2019 Feb 22. pii: jnumed.118.224170. doi: 10.2967/jnumed.118.224170.
    PubMed     Abstract available

    November 2018
  22. ZHUANG M, Vallez Garcia D, Kramer GM, Frings V, et al
    Variability and repeatability of quantitative uptake metrics in [(18)F]FDG PET/CT imaging of non-small cell lung cancer: impact of segmentation method, uptake interval, and reconstruction protocol.
    J Nucl Med. 2018 Nov 2. pii: jnumed.118.216028. doi: 10.2967/jnumed.118.216028.
    PubMed     Abstract available

    July 2018
  23. TURGEON GA, Iravani A, Akhurst T, Beaulieu A, et al
    What FDG-PET response-assessment method best predicts survival after curative-intent chemoradiation in non-small cell lung cancer (NSCLC): EORTC, PERCIST, Peter Mac or Deauville criteria?
    J Nucl Med. 2018 Jul 20. pii: jnumed.118.214148. doi: 10.2967/jnumed.118.214148.
    PubMed     Abstract available

  24. DE BRUYCKER S, Vangestel C, Van den Wyngaert T, Pauwels P, et al
    (18)F-HX4 Hypoxia PET Holds Promise as a Prognostic and Predictive Imaging Biomarker in a Lung Cancer Xenograft Model Treated with Metformin and Radiotherapy.
    J Nucl Med. 2018 Jul 6. pii: jnumed.118.212225. doi: 10.2967/jnumed.118.212225.
    PubMed     Abstract available

    May 2018
  25. HEINZMANN K, Nguyen QD, Honess DJ, Smith DM, et al
    Depicting changes in tumor biology in response to cetuximab mono- or combination therapy by apoptosis and proliferation imaging using (18)F-ICMT-11 and 3'-Deoxy-3'-[(18)F]Fluorothymidine ((18)F-FLT) PET.
    J Nucl Med. 2018 May 24. pii: jnumed.118.209304. doi: 10.2967/jnumed.118.209304.
    PubMed     Abstract available

  26. HAN Z, Xiao Y, Wang K, Yan J, et al
    Development of a Novel SPECT Tracer to Image c-Met Expression in Non-Small Cell Lung Cancer in a Human Tumor Xenograft.
    J Nucl Med. 2018 May 18. pii: jnumed.117.206730. doi: 10.2967/jnumed.117.206730.
    PubMed     Abstract available

    April 2018
  27. MCHUGH C, Thipparthi MR, Lawhorn-Crews JM, Polin L, et al
    Utilizing radiolabeled 3'-deoxy-3'-[(18)F]fluorothymidine with positron emission tomography to monitor the effect of dexamethasone on non-small cell lung cancer.
    J Nucl Med. 2018 Apr 19. pii: jnumed.117.207258. doi: 10.2967/jnumed.117.207258.
    PubMed     Abstract available

    November 2017
  28. OLIN A, Ladefoged CN, Langer NH, Keller SH, et al
    Reproducibility of MR-based Attenuation Maps in PET/MRI and the Impact on PET Quantification in Lung Cancer.
    J Nucl Med. 2017 Nov 9. pii: jnumed.117.198853. doi: 10.2967/jnumed.117.198853.
    PubMed     Abstract available

    June 2017
  29. KRAMER GM, Hoekstra OS, Boellaard R
    Reply: Repeatability of Quantitative Whole Body 18F-FDG PET/CT Uptake Measures in NSCLC Patients: Dynamic versus Test-Retest Design.
    J Nucl Med. 2017 Jun 15. pii: jnumed.117.195461. doi: 10.2967/jnumed.117.195461.

  30. KRAMER GM, Frings V, Heijtel D, Smit EF, et al
    Parametric Method Performance for Dynamic 3'-Deoxy-3'-18F-Fluorothymidine PET/CT in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Carcinoma Patients Before and During Therapy.
    J Nucl Med. 2017;58:920-925.
    PubMed     Abstract available

    May 2017
  31. FLEDELIUS J, Winther-Larsen A, Khalil AA, Bylov CM, et al
    18F-FDG-PET/CT for very early response evaluation predicts CT response in Erlotinib treated NSCLC patients - A comparison of assessment methods.
    J Nucl Med. 2017 May 10. pii: jnumed.117.193003. doi: 10.2967/jnumed.117.193003.
    PubMed     Abstract available

  32. STEIGER S, Arvanitakis M, Sick B, Weder W, et al
    Analysis of prognostic values of various PET metrics in preoperative FDG PET for early stage bronchial carcinoma for progression free and overall survival: significantly increased glycolysis is a predictive factor.
    J Nucl Med. 2017 May 10. pii: jnumed.117.189894. doi: 10.2967/jnumed.117.189894.
    PubMed     Abstract available

    April 2017
  33. MORBELLI S, Alama A, Ferrarazzo G, Coco S, et al
    Circulating tumor DNA reflects tumor metabolism rather than tumor burden in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC): an 18F-FDG PET/CT study.
    J Nucl Med. 2017 Apr 27. pii: jnumed.117.193201. doi: 10.2967/jnumed.117.193201.
    PubMed     Abstract available

    March 2017
  34. WARNDERS FJ, Terwisscha van Scheltinga AG, Knuehl C, van Roy M, et al
    HER3 specific biodistribution and tumor uptake of 89Zr-MSB0010853 visualized by real-time and non-invasive PET imaging.
    J Nucl Med. 2017 Mar 30. pii: jnumed.116.181586. doi: 10.2967/jnumed.116.181586.
    PubMed     Abstract available

  35. USMANIJ EA, Natroshvili T, Timmer-Bonte JN, Oyen WJ, et al
    The predictive value of early in-treatment FDG-PET/CT response to chemotherapy in combination with bevacizumab in advanced non-squamous non-small cell lung cancer.
    J Nucl Med. 2017 Mar 23. pii: jnumed.116.185314. doi: 10.2967/jnumed.116.185314.
    PubMed     Abstract available

    January 2017
  36. HEKMAN MC, Rijpkema M, Bos D, Oosterwijk E, et al
    Detection of micrometastases using SPECT/fluorescence dual-modality imaging in a CEA-expressing tumor model.
    J Nucl Med. 2017 Jan 26. pii: jnumed.116.185470. doi: 10.2967/jnumed.116.185470.
    PubMed     Abstract available

    December 2016
  37. NOTNI J, Reich D, Maltsev OV, Kapp TG, et al
    In-vivo PET imaging of the "cancer integrin" alphavbeta6 using gallium-68 labelled cyclic RGD nonapeptides.
    J Nucl Med. 2016 Dec 15. pii: jnumed.116.182824.
    PubMed     Abstract available

    May 2016
  38. CYSOUW MC, Kramer GM, Hoekstra OS, Frings V, et al
    Accuracy and precision of partial volume correction in oncological PET/CT studies.
    J Nucl Med. 2016 May 26. pii: jnumed.116.173831.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.